Linked Life Data

1515256

Source:http://linkedlifedata.com/resource/pubmed/id/1515256

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
8-9
pubmed:dateCreated
1992-10-8
pubmed:abstractText
The results of high-dose chemotherapy with melphalan or melphalan (carmustine) etoposide for 66 consecutive patients with relapsed or resistant Hodgkin's disease are described. 55 patients were evaluable for response and 22% of these achieved complete remission and 59% partial remission. The actuarial survival at 2 years was 45% and the principal factors determining survival were the sensitivity of the disease to therapy given before high-dose chemotherapy and the type of treatment received. Intensive chemotherapy with autologous bone marrow transplantation can produce long-term survivors among patients for whom long-term survival would otherwise be improbable. However, this treatment remains toxic with an uncertain place in management.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0959-8049
pubmed:author
pubmed:issnType
Print
pubmed:volume
28A
pubmed:owner
NLM
pubmed:authorsComplete
N
pubmed:pagination
1396-400
pubmed:dateRevised
2006-4-24
pubmed:meshHeading
pubmed:year
1992
pubmed:articleTitle
High-dose chemotherapy and autologous bone marrow transplantation for relapsed and refractory Hodgkin's disease.
pubmed:affiliation
Yorkshire Cancer Research Campaign, Institute for Cancer Studies, St. James's University Hospital, U.K.
pubmed:publicationType
Journal Article